StreetAlpha
13F holdings · Q3 2026

Davern Capital Partners

NY, NY · files as Davern Capital Partners, LP
Know the moment Davern Capital Partners filesYou follow Davern Capital Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 12, 2026Next filing due Feb 15, 2027CIK 2003147

Davern Capital Partners reported 17 stocks worth $514M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are BNTX (13.0%), RPRX (11.1%) and INSM (11.0%). Compared with Q2 2026, the fund opened new positions in ARGX, ABVX and ARWR, added to IONS, VERA and AVTX, trimmed BNTX, RPRX and INSM and sold out of ALNY, GPCR and PRCT.

Latest filing: what Davern Capital Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
5 new3 added8 trimmed3 sold outBought about $117M · sold about $184M
New 5
Added 3
Trimmed 8
See all 8 →
Sold out 3

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$514M−12.4% vs last quarter
Stocks held175 new · 3 sold out
Top 5 weight55.0%fairly concentrated
Turnover59%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
BNTX
Biontech SE
$67.1M13.0%682K−72K (−10%)4 of 4
2
RPRX
Royalty Pharma PLC
$56.9M11.1%974K−181K (−16%)4 of 4
3
INSM
Insmed Inc
$56.6M11.0%496K−64K (−11%)3 of 4
4
ROIV
Roivant Sciences Ltd
$53.9M10.5%1.5M−460K (−24%)4 of 4
5
IONS
Ionis Pharmaceuticals Inc
$48.5M9.4%1.1M+288K (+36%)4 of 4
6
ARGX
Argenx SE
$36.1M7.0%38KNew position3 of 4
7
REGN
Regeneron Pharmaceutical
$30.8M6.0%41K−52K (−56%)4 of 4
8
NTRA
Natera Inc
$26.1M5.1%63K−56K (−47%)4 of 4
9
ABVX
Abivax SA
$21.7M4.2%219KNew position3 of 4
10
VERA
Vera Therapeutics Inc
$20.3M4.0%628K+129K (+26%)2 of 4
🔒 7 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
ALNY
Alnylam Pharmaceuticals Inc
$34M113K
GPCR
Structure Therapeutics Inc
$23.9M446K
PRCT
Procept Biorobotics Corp
$10.5M465K

Reported value

last 4 quarters
$309MQ4 '25
$365MQ1 '26
$587MQ2 '26
$514MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 12, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Davern Capital Partners 13F FAQ

What does Davern Capital Partners own?

Davern Capital Partners reported 17 stocks worth $514M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are BNTX (13.0%), RPRX (11.1%) and INSM (11.0%). The table above lists every position in the filing (the top 10 without an account).

What did Davern Capital Partners buy and sell in Q3 2026?

Compared with Q2 2026: 5 new positions, 3 added to, 8 trimmed and 3 sold out. New positions include ARGX, ABVX and ARWR. It sold all of ALNY, GPCR and PRCT.

When will Davern Capital Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Davern Capital Partners's portfolio worth?

The Q3 2026 filing reports $514M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.